Cytogenetics : FISH_

DIAGNOSTIC SERVICES

Cytogenetics / Karyotyping

Karyotyping, also called whole genome chromosomal analysis, can differentiate primary and secondary changes; can address why, how, when and where chromosome abnormalities arise. Thus provide insights into diagnosis, prognosis, and prediction of disease in many acute and chronic leukemias and lymphomas. Traditional G-banding for at least 20 metaphase analyses with specific cell culturing and analyzed by two independent ASCP certified Cytogenetic Technologist ensures optimal results.

cytogenetics fish
N

Turnaround time 3-5 days

N

Over 99% culture success

N

Cell-specific culture

  • Myeloid Disorders
  • B-Lymphoid Disorders
  • T-Lymphoid Disorders
  • Myeloma

FISH

Fluorescence in situ hybridization (FISH) is a molecular cytogenetic method, and works as an adjunct to karyotype analysis for the detection of cytogenetic abnormalities. FISH can help provide clarification of G-banded abnormalities or identify cryptic abnormalities not visible by karyotype analysis. The main advantages of FISH include: high sensitivity and specificity, rapid turnaround time, capacity to analyze large numbers of cells, and ability to obtain adequate data from samples with a low mitotic index or terminally differentiated cells. Also, dividing cells are not required for FISH analysis using both fresh tissue and paraffin embedded tissue.

In general, two hundred interphase cells are analyzed per probe by two independent ASCP certified Cytogenetic Technologist (100 cells/reader).

FISH is most useful when the analysis is targeted toward specific translocation, rearrangement and gain or loss that are known to be associated with a particular disease. We offer the following Disease-focused FISH panels with the best-in-industry turnaround time (1-2 days )

N

Turnaround time 2 days

N

Same day results for STAT cases

N

Complete suite of hematopoietic FISH probes

N

Disease-focused panels for

FISH PANELS

CLL

PROBE
CCND1/IGH (11q13.3/14q32.3)
CEP 12 (p11.1-q11)
D13S319 (13q14.3)
LAMP1 (13q34)
ATM (11q22.3)
TP53 (17p13.1)

 

MM

PROBE
1p36/1pTEL/1q25
FGFR3/IGH (4p16/14q32)
CEP 9 (p11-q11)/
CEP 15 (p11.2)/
TP53 (17p13.1)
CCND1/IGH (11q13.3/14q32.3)
D13S319 (13q14.3)/
LAMP1 (13q34)
IGH ba (14q32.2)
IGH/MAF (14q32/16q23)
IGH/MAFB (14q32/20q12)

CML

PROBE
ASS1-ABL1/BCR (9q34.1/22q11.2)

 

MPN

PROBE
CEP 8 (p11.1-q11.1)
ETV6 ba (12p13.2)
D13S319/LAMP1 (13q14.3/13q34)
D20S108 (20q12)

 

AML

PROBE
D5S23,D5S721/EGR1 (5p15.2/5q31)
D7S522/CEP 7 (7q31/7p11.1-q11.1)
RUNX1T1/RUNX1 (8q21.3/21q22)
MLL (11q23)
PML/RARA (15q24/17q21.1-21.2)
CBFB (16q22)

 

Eosinophilia-FISH

Eosinophilia
PDGFRA (4q12)
PDGFRB (5q32)
FGFR1 (8p11.23-p11.22)
PCM1/JAK2 (8p22/9pq24.1)

MDS

PROBE
D7S522/CEP 7 (7q31/7p11.1-q11.1)
D5S23,D5S721/EGR1 (5p15.2/5q31)
CEP 8 (p11.1-q11.1)
ETV6 (12p13.2)
D20S108 (20q12)

 

LYMPHOMA

High Grade Lymphoma
BCL6 ba (3q27)
MYC ba (8q24.21)
IGH/BCL2 (14q32.3/18q21.3)

 

Marginal Zone Lymphoma
CEP 3 (3p11.1-q11.1)
MYB (6q23.2-q23.3)
CEP 7/D7S522
(7p11.1-q11.1/7q31)
CCND1/IGH
(11q13.3/14q32.3)
BIRC3/MALT1 (11q22.1/18q21.3)

 

T-Cell Lymphoma
CEP 7/D7S522
(7p11.1-q11.1/7q31)
IGH ba (14q32.3)
MYC/IGH/CEP 8 (8q24.2/14q32.3/8p11.-q11.1)